Archer Develops Early Biochip Prototype for Potassium Monitoring
Archer Materials Limited has completed its alpha prototype of a blood potassium sensor integrated with a biochip. This development is crucial for clinical workflows and at-home monitoring of potassium levels, particularly for patients with chronic kidney disease and heart failure.
This milestone represents the first major step in translating Archer’s Biochip technology from individual laboratory devices into a product suitable for clinical workflows and, ultimately, point of care and at-home potassium monitoring.
The post Archer Develops Early Biochip Prototype appeared first...
AI Summary
Archer Materials Limited has completed its alpha prototype of a blood potassium sensor integrated with a biochip. This development is crucial for clinical workflows and at-home monitoring of potassium levels, particularly for patients with chronic kidney disease and heart failure.
FAQs
What is the purpose of Archer's biochip prototype?
The biochip prototype is designed for accurate blood potassium monitoring, which is essential for patients with conditions like chronic kidney disease and heart failure.
What accuracy does the alpha prototype achieve?
The alpha prototype demonstrates potassium measurement accuracy within ±0.3 mM, meeting clinical standards.
How much blood is required for testing?
The prototype requires only 10μL of blood, making it compatible with standard finger-prick tests.
What are the next steps for Archer's biochip technology?
Archer is developing a beta prototype, which will be used for negotiations with MedTech companies and to initiate clinical trials.
Who is the CEO of Archer Materials?
Dr. Simon Ruffell is the CEO of Archer Materials.
AI-assisted summary generated on Feb 18, 2026. Source link below.